Theratechnologies

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its first quarter of fiscal 2022 ended February 28, 2022 on Wednesday, April 13, 2022.

Theratechnologies to Announce Financial Results for Its First Quarter 2022

MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three poster abstracts have been accepted for presentation at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company will present new in vivo TH1902 preclinical data demonstrating tumor growth inhibition of human cancer stem-like cells (CD133+) in both triple-negative breast and ovarian cancers. Theratechnologies will also present new in vivo data on anti-cancer efficacy of TH1902 against ovarian and endometrial cancers, in addition to the inhibitory effect of TH1902 on subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model.

Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers

Theratechnologies Inc. (THTX) CEO Denis Boucher on FY2021 Results - Earnings Call Transcript

- FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV ® sales

Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update

MONTREAL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the presentation of positive results from the Phase 3 study evaluating an intravenous (IV) push method of administration of Trogarzo® for the treatment of human immunodeficiency virus type 1 (HIV-1). The results, presented as a poster at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12–16, 2022, demonstrated that there was no significant difference in pharmacokinetics between IV Push and IV Infusion of Trogarzo®.

Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022

- Top Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies' from its current partner contract sales organization

Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force

MONTREAL, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its fourth quarter of fiscal 2021 ended November 30, 2021 as well as for its full fiscal year 2021 on Thursday, February 24, 2022.

Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021

sBLA submission with FDA follows on the back of recently announced positive TMB-302 study results sBLA submission with FDA follows on the back of recently announced positive TMB-302 study results

Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV

MONTREAL, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovation Award in the “Life Sciences” category at the 31st ADRIQ Innovation Awards Gala held on November 25, 2021.

Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category

MONTREAL , Nov. 23, 2021 /PRNewswire/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-10. The filing is made for the purpose of restoring the original financing capacity which was available to Theratechnologies under its previous base shelf prospectus dated November 15, 2019 expiring on December 15, 2021.

Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended

MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 at 9:40 a.m. ET.

Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021

MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, for the reimbursement of Trogarzo® for eligible people aged 18 and older living with multi-drug resistant (MDR) HIV-1.

Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1

MONTREAL, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the publication of a peer-reviewed article demonstrating that the Company's novel investigational peptide-drug conjugates (PDCs) TH1902 and TH1904, derived from its SORT1+ Technology™, are effective in inhibiting vasculogenic mimicry (VM) in in vitro ovarian and triple negative breast cancer (TNBC) models.

Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry

Theratechnologies Inc. (THTX) CEO Paul Levesque on Q3 2021 Results - Earnings Call Transcript

Theratechnologies Inc (NASDAQ: THTX) reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed the consensus of $19.66 million.

Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline

- Q3 FY2021 consolidated sales grow 27% over Q3 FY2020 –

Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update

MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer, will participate at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 4:30 p.m. ET.

Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference

MONTREAL, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its third quarter of fiscal 2021 ended August 31, 2021 on Wednesday, October 13, 2021.

Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021

Theratechnologies Inc (NASDAQ: THTX) has announced results from a study evaluating an intravenous (IV) push form of Trogarzo (ibalizumab-uiyk) for HIV-1 infection. The TMB-302 study was conducted by the Company's partner, TaiMed Biologics, to evaluate the current Trogarzo IV Infusion with a more convenient IV Push form that can be infused within 30 seconds without dilution to the 15-minute infusion time of the original IV Infusion.

Theratechnologies' IV Push Form Of HIV Treatment At Par With IV Infusion

- TMB-302 study results demonstrate that there was no difference in pharmacokinetics between IV Push and IV Infusion -

Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study

MONTREAL, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021 at 10:00 a.m. ET.

Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021

MONTREAL, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical research of TH1902 for the treatment of sortilin-positive triple negative breast cancer (TNBC) in the peer-reviewed journal Cancer Science, confirming the in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism.

Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

Theratechnologies Inc. (THTX) CEO Paul Levesque on Q2 2021 Results - Earnings Call Transcript

Theratechnologies Inc (NASDAQ: THTX) has completed discussions with the FDA and European Medicines Agency regarding its proposed trial design and protocol for its Phase 3 trial for tesamorelin in nonalcoholic steatohepatitis (NASH). The trial will include a futility analysis after approximately 400 patients have completed 18 months of treatment and have received a second liver biopsy.

Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings

MONTREAL, July 15, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported financial results for the second quarter ended May 31, 2021 (Q2 Fiscal 2021) and provided an update on its planned Phase 3 clinical trial evaluating tesamorelin for the treatment of nonalcoholic steatohepatitis (NASH).

News for Theratechnologies Stock (THTX)